NO20006312L - Therapeutic mixtures of selective estrogen receptor modulators (SERMs) and growth hormone secretion stimulants (GHS) for the treatment of musculoskeletal fragility - Google Patents
Therapeutic mixtures of selective estrogen receptor modulators (SERMs) and growth hormone secretion stimulants (GHS) for the treatment of musculoskeletal fragilityInfo
- Publication number
- NO20006312L NO20006312L NO20006312A NO20006312A NO20006312L NO 20006312 L NO20006312 L NO 20006312L NO 20006312 A NO20006312 A NO 20006312A NO 20006312 A NO20006312 A NO 20006312A NO 20006312 L NO20006312 L NO 20006312L
- Authority
- NO
- Norway
- Prior art keywords
- ghs
- serms
- treatment
- growth hormone
- fragility
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Denne oppfinnelsen er rettet mot farmasøytiske kombinasjonsblandinger og fremgangsmåter inneholdende (-)-cis-6-fenyl-5-(4-(2-pyrrolidin-1-yl-etoksy)- fenyl)-5,6,7,8-tetrahydronaftalen-2-ol eller et farmasøytisk akesptabelt salt derav og2-amino-N-(2-(3a(R)-benzyl-2-metyl-3-okso-213,3a,4,6,7-heksahydropyra2olo- [4,3-c]pyridin-5-yl)-1(R)-benzyloksymetyl-2-oksoetyl)-isobutyramid eller et farma- søytisk akesptabelt salt derav, fremgangsmåter for anvendelse av slike blandinger og sett som inneholder slike blandinger. Blandingene kan anvendes for å be- handle muskelskjelett-skjørhet, inkludert osteoporose, osteoporotisk fraktur, lav benmasse, skjørhet, og lav muskelmasse.This invention is directed to pharmaceutical combination compositions and processes containing (-) - cis-6-phenyl-5- (4- (2-pyrrolidin-1-yl-ethoxy) -phenyl) -5,6,7,8-tetrahydronaphthalene 2-ol or a pharmaceutically acceptable salt thereof and 2-amino-N- (2- (3a (R) -benzyl-2-methyl-3-oxo-213,3a, 4,6,7-hexahydropyr 2 -olo [4.3 (c] pyridin-5-yl) -1 (R) -benzyloxymethyl-2-oxoethyl) -isobutyramide or a pharmaceutically acceptable salt thereof, methods of using such compositions and sets containing such mixtures. The compositions can be used to treat musculoskeletal fragility, including osteoporosis, osteoporotic fracture, low bone mass, fragility, and low muscle mass.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8946998P | 1998-06-16 | 1998-06-16 | |
| PCT/IB1999/001117 WO1999065486A1 (en) | 1998-06-16 | 1999-06-16 | Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20006312L true NO20006312L (en) | 2000-12-12 |
| NO20006312D0 NO20006312D0 (en) | 2000-12-12 |
Family
ID=22217825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20006312A NO20006312D0 (en) | 1998-06-16 | 2000-12-12 | Therapeutic mixtures of selective estrogen receptor modulators (SERM) and growth hormone secretion stimulant (GHS) for the treatment of musculoskeletal fragility |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1087764A1 (en) |
| JP (1) | JP2002518326A (en) |
| KR (1) | KR20010052852A (en) |
| CN (1) | CN1301160A (en) |
| AP (1) | AP9901582A0 (en) |
| AR (1) | AR018869A1 (en) |
| AU (1) | AU4054799A (en) |
| BG (1) | BG105041A (en) |
| BR (1) | BR9911324A (en) |
| CA (1) | CA2335134A1 (en) |
| CO (1) | CO5070587A1 (en) |
| EA (1) | EA200001186A1 (en) |
| GT (1) | GT199900087A (en) |
| HN (1) | HN1999000097A (en) |
| HR (1) | HRP20000859A2 (en) |
| HU (1) | HUP0102505A3 (en) |
| ID (1) | ID27599A (en) |
| IL (1) | IL138630A0 (en) |
| IS (1) | IS5691A (en) |
| MA (1) | MA26652A1 (en) |
| NO (1) | NO20006312D0 (en) |
| OA (1) | OA11505A (en) |
| PA (1) | PA8475901A1 (en) |
| PE (1) | PE20000646A1 (en) |
| PL (1) | PL344981A1 (en) |
| SK (1) | SK18912000A3 (en) |
| TN (1) | TNSN99124A1 (en) |
| TR (1) | TR200003544T2 (en) |
| WO (1) | WO1999065486A1 (en) |
| ZA (1) | ZA993975B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2360103A1 (en) * | 1999-02-08 | 2000-08-17 | Robert Sladek | Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding orphan nuclear receptor erralpha |
| DE60124616T2 (en) | 2000-05-08 | 2007-09-13 | Pfizer Products Inc., Groton | Enzymatic cleavage of selective modulators of the estrogen receptor |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| CA2420535A1 (en) * | 2000-08-30 | 2002-03-07 | Mary Tanya Am Ende | Sustained release formulations for growth hormone secretagogues |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| WO2006024931A2 (en) * | 2004-08-31 | 2006-03-09 | Pfizer Products Inc. | Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator |
| CU23558A1 (en) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE |
| EP2118080B1 (en) | 2007-02-09 | 2016-08-31 | Ocera Therapeutics, Inc. | Macrocyclic ghrelin receptor modulators and methods of using the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA51676C2 (en) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (en) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | COMBINED THERAPY FOR OSTEOPOROSIS |
-
1999
- 1999-06-15 ZA ZA9903975A patent/ZA993975B/en unknown
- 1999-06-15 PE PE1999000528A patent/PE20000646A1/en not_active Application Discontinuation
- 1999-06-15 PA PA19998475901A patent/PA8475901A1/en unknown
- 1999-06-15 AP APAP/P/1999/001582A patent/AP9901582A0/en unknown
- 1999-06-15 AR ARP990102848A patent/AR018869A1/en not_active Application Discontinuation
- 1999-06-15 HN HN1999000097A patent/HN1999000097A/en unknown
- 1999-06-16 PL PL99344981A patent/PL344981A1/en not_active Application Discontinuation
- 1999-06-16 JP JP2000554366A patent/JP2002518326A/en active Pending
- 1999-06-16 HU HU0102505A patent/HUP0102505A3/en unknown
- 1999-06-16 AU AU40547/99A patent/AU4054799A/en not_active Abandoned
- 1999-06-16 ID IDW20002627A patent/ID27599A/en unknown
- 1999-06-16 EA EA200001186A patent/EA200001186A1/en unknown
- 1999-06-16 SK SK1891-2000A patent/SK18912000A3/en unknown
- 1999-06-16 MA MA25628A patent/MA26652A1/en unknown
- 1999-06-16 CO CO99037622A patent/CO5070587A1/en unknown
- 1999-06-16 TR TR2000/03544T patent/TR200003544T2/en unknown
- 1999-06-16 TN TNTNSN99124A patent/TNSN99124A1/en unknown
- 1999-06-16 IL IL13863099A patent/IL138630A0/en unknown
- 1999-06-16 CA CA002335134A patent/CA2335134A1/en not_active Abandoned
- 1999-06-16 CN CN99806237A patent/CN1301160A/en active Pending
- 1999-06-16 WO PCT/IB1999/001117 patent/WO1999065486A1/en not_active Application Discontinuation
- 1999-06-16 KR KR1020007014186A patent/KR20010052852A/en not_active Application Discontinuation
- 1999-06-16 GT GT199900087A patent/GT199900087A/en unknown
- 1999-06-16 EP EP99923802A patent/EP1087764A1/en not_active Withdrawn
- 1999-06-16 BR BR9911324-4A patent/BR9911324A/en not_active Application Discontinuation
-
2000
- 2000-10-20 OA OA1200000290A patent/OA11505A/en unknown
- 2000-10-27 IS IS5691A patent/IS5691A/en unknown
- 2000-12-11 BG BG105041A patent/BG105041A/en unknown
- 2000-12-12 NO NO20006312A patent/NO20006312D0/en not_active Application Discontinuation
- 2000-12-14 HR HR20000859A patent/HRP20000859A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0102505A3 (en) | 2002-12-28 |
| AR018869A1 (en) | 2001-12-12 |
| PE20000646A1 (en) | 2000-08-05 |
| AP9901582A0 (en) | 1999-06-30 |
| PA8475901A1 (en) | 2000-05-24 |
| ID27599A (en) | 2001-04-12 |
| KR20010052852A (en) | 2001-06-25 |
| WO1999065486A1 (en) | 1999-12-23 |
| OA11505A (en) | 2004-05-07 |
| BG105041A (en) | 2001-08-31 |
| AU4054799A (en) | 2000-01-05 |
| SK18912000A3 (en) | 2001-10-08 |
| IS5691A (en) | 2000-10-27 |
| MA26652A1 (en) | 2004-12-20 |
| HUP0102505A2 (en) | 2001-11-28 |
| IL138630A0 (en) | 2001-10-31 |
| BR9911324A (en) | 2001-04-03 |
| HN1999000097A (en) | 1999-11-03 |
| PL344981A1 (en) | 2001-11-19 |
| CA2335134A1 (en) | 1999-12-23 |
| NO20006312D0 (en) | 2000-12-12 |
| CN1301160A (en) | 2001-06-27 |
| EP1087764A1 (en) | 2001-04-04 |
| JP2002518326A (en) | 2002-06-25 |
| HRP20000859A2 (en) | 2001-04-30 |
| TNSN99124A1 (en) | 2005-11-10 |
| TR200003544T2 (en) | 2001-04-20 |
| CO5070587A1 (en) | 2001-08-28 |
| ZA993975B (en) | 2000-12-15 |
| EA200001186A1 (en) | 2001-06-25 |
| GT199900087A (en) | 2000-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MacDermid et al. | Distal radius fracture: a prospective outcome study of 275 patients | |
| Jordan et al. | The Evolution of the Ilizarov Technique. | |
| EP0911321A3 (en) | Compounds for the treatment of osteoporosis | |
| DE60037836D1 (en) | ThiazoloÄ4,5-diphyrimidine compounds for the treatment of rheumatoid arthritis | |
| WO1998058911A3 (en) | Prostaglandin agonists | |
| NO20006312L (en) | Therapeutic mixtures of selective estrogen receptor modulators (SERMs) and growth hormone secretion stimulants (GHS) for the treatment of musculoskeletal fragility | |
| DK217588D0 (en) | 17BETA- (CYCLOPROPYLAMINO) -ANDROST-5-EN-3BETA OLDER DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINAL PRODUCTS | |
| BG105125A (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone | |
| NO20006381L (en) | Therapeutic combinations of (selective) estrogen receptor modulators (SERM) and growth hormone secretion agents | |
| NZ504051A (en) | Crystalline polymorphs of 1,3-di-cyclopropylmethyl-8-amino xanthine (cypamfylline), and the use of these compounds for treating PDE4 or TNF mediated diseases | |
| CA2274381A1 (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2 | |
| ECSP993020A (en) | COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY | |
| ECSP993021A (en) | THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY | |
| Endo et al. | The intramedullary gradual elongation nail: Application for femoral shaft non-union | |
| TODANI | A follow-up study of the subtrochanteric osteotomy for the treatment of the irreducible congenital dislocation of the hip | |
| Kojima et al. | Treatment for Proximal Humeral Fractures of Elderly Patients with Spiral Pin | |
| Ikemoto et al. | Treatment of Fracture-Dislocation of the Ankle | |
| Hajime et al. | The Improvement of the Upper Extremity Function in Cerebral Palsy | |
| Kim | Clinical Observation on Metastatic Bone Cancers | |
| Mizokami et al. | Application of cast brac for fractures of the lower extremities | |
| Fukushima et al. | The Y-shaped Plate for the Fractures around the Joint | |
| Whitman | TREATMENT OF FRACTURES OF NECK OF FEMUR | |
| TH57984A3 (en) | A therapeutic combination consisting of selective estrogen receptor modulators and parathyroid hormone. | |
| ECSP993016A (en) | THERAPEUTIC COMBINATIONS INCLUDING A SELECTIVE ESTROGEN RECEPTOR AND PARATOROID HORMONE MODULATOR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |